<DOC>
	<DOCNO>NCT00420082</DOCNO>
	<brief_summary>This randomize , double blind , active placebo control , 4 way crossover study patient seasonal allergic rhinitis . Patients receive single dose bilastine 20 mg , Cetirizine 10 mg , Fexofenadine 120 mg , placebo Vienna Challenge Chamber .</brief_summary>
	<brief_title>A Randomized , Double-Blind , 4-way Crossover Study Evaluate Efficacy Bilastine Vienna Challenge Chamber</brief_title>
	<detailed_description>The objective study determine effect single dose bilastine 20 mg nasal symptom allergic rhinitis provoke spending 4 hour Vienna Challenge Chamber . This effect compare action Cetirizine 10 mg , Fexofenadine 120 mg , placebo . To explore onset action , patient receive study drug two hour start provocation Day 1.Patients remain theVCC additional four hour . On Day 2 , patient return VCC post-dose hour 22-26 .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>Have history seasonal allergic rhinitis Have positive ( define protocol ) skin prick RAST test within 12 month prior screen visit Have clinically significant illness disease Have unstable asthma Has participate clinical trial 30 day prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Rhinitis</keyword>
	<keyword>Seasonal</keyword>
	<keyword>Allergic</keyword>
	<keyword>Pollen allergy</keyword>
	<keyword>Environmental Exposure Chamber</keyword>
	<keyword>Challenge Chamber</keyword>
</DOC>